Anzeige
Mehr »
Dienstag, 10.03.2026 - Börsentäglich über 12.000 News
Verdoppelt - und noch nicht am Ziel? Dieser Rohstoff-Explorer profitiert vom Antimon-Boom
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0Q8LD | ISIN: BMG210A71016 | Ticker-Symbol: MX6A
Tradegate
09.03.26 | 15:19
0,820 Euro
+1,86 % +0,015
Branche
Gesundheitswesen
Aktienmarkt
ASIEN
1-Jahres-Chart
GRAND PHARMACEUTICAL GROUP LTD Chart 1 Jahr
5-Tage-Chart
GRAND PHARMACEUTICAL GROUP LTD 5-Tage-Chart
RealtimeGeldBriefZeit
0,7350,83009.03.
0,7800,83009.03.

Aktuelle News zur GRAND PHARMACEUTICAL GROUP Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
03.02.GRAND PHARMA (00512): SUPPLEMENTAL AND CLARIFICATION ANNOUNCEMENT - CONNECTED TRANSACTION - ACQUISITION OF THE ENTIRE EQUITY INTERESTS IN HEBEI YUANDA ...6
GRAND PHARMACEUTICAL GROUP Aktie jetzt für 0€ handeln
19.01.GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: THE NDA OF THE GROUP'S GLOBAL INNOVATIVE RDC TLX591-CDX IS ACCEPTED BY THE NMPA1
31.12.25GRAND PHARMA (00512): CONNECTED TRANSACTION: ACQUISITION OF THE ENTIRE EQUITY INTERESTS IN HEBEI YUANDA JIUFU BIOTECHNOLOGY CO., LTD. AND BAODING JIAHE ...1
29.12.25GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: THE WORLD'S FIRST ADRENALINE NASAL SPRAY INTRODUCED BY THE GROUP FOR THE TREATMENT OF SEVERE ALLERGIC REACTIONS ...1
23.12.25GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: THE GROUP INTRODUCES THE WORLD'S FIRST ADRENALINE NASAL SPRAY FOR THE TREATMENT OF SEVERE ALLERGIC REACTIONS2
17.12.25GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: THE GROUP'S INDEPENDENTLY DEVELOPED, BLOCKBUSTER, GLOBALLY INNOVATIVE RADIONUCLIDE-DRUG CONJUGATE, GPN01530, ...-
08.12.25GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: THE PHASE II CLINICAL TRIAL IN CHINA OF THE GROUP'S CLASS 1 INNOVATIVE TRADITIONAL CHINESE MEDICINE GPN01360 ...1
04.12.25GRAND PHARMA (00512): SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE 2021 AND 2022 ANNUAL REPORTS1
10.11.25GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: GLOBAL INNOVATIVE COMBINATION PRODUCT RYALTRIS NASAL SPRAY IS APPROVED TO BE COMMERCIALIZED IN CHINA1
09.10.25GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: THE REGISTRATION CLINICAL STUDY CONDUCTED IN CHINA OF THE GLOBAL INNOVATIVE TEMPERATURE-SENSITIVE EMBOLIC ...-
24.09.25GRAND PHARMA (00512): INTERIM REPORT 20251
24.09.25GRAND PHARMA (00512): NOTIFICATION LETTER AND REPLY FORM TO NON-REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF INTERIM REPORT-
24.09.25GRAND PHARMA (00512): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF INTERIM REPORT-
23.09.25GRAND PHARMA (00512): VOLUNTARY ANNOUNCEMENT: TREPROSTINIL INJECTION (20ML: 50MG) IS GRANTED A DRUG REGISTRATION CERTIFICATE3
08.09.25Sirtex Medical Inc.: Sirtex Receives Expanded CE Mark Approval for SIR-Spheres Y-90 Resin Microspheres393Broadened indication increases access to liver cancer treatment across Europe and CE-marked territories. WOBURN, Mass., Sept. 8, 2025 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading...
► Artikel lesen
07.07.25SIR-Spheres Y-90 Harz-Mikrosphären von Sirtex Medical erhalten FDA-Zulassung für die Behandlung des inoperablen Leberzellkarzinoms503Woburn, Massachusetts (ots/PRNewswire) - Erweiterte Indikation macht SIR-Spheres® zur ersten und einzigen Radioembolisationstherapie in den USA, die sowohl zur Behandlung des inoperablen Leberzellkarzinoms...
► Artikel lesen
07.07.25Sirtex Medical Inc.: Sirtex Medical's SIR-Spheres Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable Hepatocellular Carcinoma347Expanded indication makes SIR-Spheres® the first and only radioembolization therapy in the U.S. approved to treat both unresectable hepatocellular carcinoma and metastatic colorectal cancer WOBURN...
► Artikel lesen
07.05.25Grand Pharmaceutical Group Limited: The world's first: Grand Pharma's global innovative product STC3141 successfully reached the clinical endpoint in the Phase II clinical study in China535The results showed that the SOFA scores of the drug treatment groups on the 7th day were significantly lower than those of the baseline, especially in the high-dose group, where the decrease...
► Artikel lesen
14.04.25Dividendenbekanntmachungen (14.04.2025)4.755 Unternehmen  ISIN-Code  Dividende (Währung)  Dividende (EUR)  CLIQ DIGITAL AG  DE000A35JS40 - 0,04 EUR  COMET HOLDING AG  CH0360826991  1,5 CHF  1,6197 EUR  EMMI AG  CH0012829898  16,5 CHF  17,8174...
► Artikel lesen
19 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1